Department of Oral Pathology, Field of Oncology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan.
Oncol Rep. 2010 Mar;23(3):739-44.
The genotype of the fibroblast growth factor receptor 4 (FGFR4) gene and TP53 mutation have been reported as prognostic factors for cancers of the head and neck, bladder, breast and colon. To determine whether they are applicable for oral squamous cell carcinoma (OSCC), we investigated these two genes in OSCC samples from 150 patients who had undergone radical surgery and in 100 cancer-free individuals. In OSCC, the FGFR4 Gly388Arg polymorphism and the presence or absence of mutation in TP53 did not show a significant association with the clinicopathological features of the tumors at surgery. However, the FGFR4 Arg388 allele, as well as mutations in TP53, was found to be closely associated with poor prognosis. Moreover, these two parameters synergistically affected the survival of OSCC patients. During 60 months of observation after radical surgery, a majority of patients with homozygous Arg388 FGFR4 plus mutated TP53 died of cancer, whereas >90% patients carrying homozygous Gly388 FGFR4 plus wild-type TP53 survived. Therefore, the FGFR4 Gly388Arg polymorphism and TP53 mutations, as well as their combinations, are excellent predictors of the prognosis for OSCC patients.
成纤维细胞生长因子受体 4（FGFR4）基因的基因型和 TP53 突变已被报道为头颈部、膀胱、乳腺和结肠癌症的预后因素。为了确定它们是否适用于口腔鳞状细胞癌（OSCC），我们在 150 例接受根治性手术的 OSCC 样本和 100 例无癌个体中研究了这两个基因。在 OSCC 中，FGFR4 Gly388Arg 多态性和 TP53 突变的存在与否与手术时肿瘤的临床病理特征没有显著相关性。然而，FGFR4 Arg388 等位基因以及 TP53 的突变与不良预后密切相关。此外，这两个参数协同影响 OSCC 患者的生存。在根治性手术后 60 个月的观察期间，大多数 FGFR4 纯合子 Arg388 加上 TP53 突变的患者死于癌症，而携带 FGFR4 纯合子 Gly388 加上野生型 TP53 的患者中有>90%存活。因此，FGFR4 Gly388Arg 多态性和 TP53 突变及其组合是 OSCC 患者预后的优秀预测指标。
